Ophthalmology
Tenpoint expects to launch its Yuvezzi eye drops in early Q2, where it will compete with other rivals such as LENZ’s Vizz, as well as more traditional options such as glasses and lenses.
Multiple Chinese biotechs are seeking to raise new funds through IPOs on the Hong Kong and Beijing stock exchanges to support international clinical trials for their first-in-class molecules.
The company announced positive preliminary results from its Phase II study of the gene therapy in geographic atrophy secondary to dry age-related macular degeneration.
Promising Phase III results could help tinlarebant become the first approved treatment for the genetic eye disorder, with planned US FDA filing in 2026.
Deal Snapshot: Eli Lilly has become increasingly interested in genetic treatments for the eye and has secured the rights to a high-profile gene therapy for a rare form of childhood blindness.
On the back of long-term durability data expected from a Phase II study in the fourth quarter, NovaBridge plans to advance VIS-101 into a Phase III head-to-head trial against Roche’s Vabysmo.
The company will ask regulators to consider the totality of the data for vamikibart and look past the failure of one of its Phase III trials
Multiple Chinese biopharma firms reach new deals with major Western and other partners in a spree of licensing deals over a one-day period, with ADCs, in vivo CAR and bifunctional fusion protein therapies among the target assets.
Chief medical officer Eliav Barr and EyeBio chief scientific officer Tony Adamis talk to Scrip about progress in eye diseases post Merck’s EyeBio acquisition.
Another biotech is facing the threat of closure after its lead candidate failed a Phase II study in a front-of-eye disease.
New cash will increase its total assets under management to over $1.4bn.
The Swiss company believes new rigor in its internal decision-making and focus on best-in-class efficacy will deliver strong growth to 2030 and beyond.
The start-up, which spent two years operating in stealth mode, has a clinical-stage anti-VEGF/Ang2 drug to rival Roche’s Vabysmo, and is on the hunt for additional ophthalmology assets.
Emerging company profile: PulseSight Therapeutics is developing non-viral gene therapies for AMD, led by PST-611 for geographic atrophy. Its electro-transfection platform aims for durable protein expression and reduced injection frequency.
The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.
The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.
Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.
4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.
Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.